Taiji Group subsidiary gets clinical trial approval for semaglutide

Chongqing Taiji Industry Group Co., Ltd. announced that its wholly-owned subsidiary, Taiji Group Chongqing Fuling Pharmaceutical Factory Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of semaglutide injection. This approval, granted on July 4, 2025, allows the company to proceed with clinical trials for the treatment of type 2 diabetes, classifying the drug as a 3.3 biosimilar.

Semaglutide is a long-acting GLP-1 receptor agonist, crucial for stimulating insulin production, inhibiting glucagon secretion, and reducing appetite, thereby playing a vital role in managing type 2 diabetes and assisting with weight control. The approved indication is for adults with type 2 diabetes whose blood sugar remains uncontrolled despite diet, exercise, and treatment with metformin and/or sulfonylureas, as well as for reducing major cardiovascular events.

To date, Taiji Group has invested approximately RMB 44.1834m in research and development for this project. Following the completion of clinical trials, the company plans to submit the data and relevant information to the National Medical Products Administration for production approval. The original semaglutide injection, developed by Novo Nordisk Inc., generated total revenue of $29.296bn in 2024.